Brought to you by 
Wyeth and Catalyst partner for Factor VIIa projects; Pfizer ends deal
11 Dec 2015
Executive Summary
Catalyst Biosciences (protein therapeutics) and Wyeth Pharmaceuticals have partnered again, this time for the development of Factor VIIa compounds for hemophilia and other bleeding conditions.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Wyeth and Catalyst partner for Factor VIIa projects; Pfizer ends deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice